Hints and tips:
...Losing the pharma licence might limit SpectrumX to hand gels and detox tunnels....
...“It’s the biggest vaccine programme in history and the logistics are enormous,” said Dr Nigel Watson, chief executive of the Wessex Local Medical Committees....
...Pharma investors have grown to ignore such earnings accretion calculations....
...A former Bausch & Lomb executive, the 49-year-old built Allergan through a succession of deals that began in 2013 when the company he ran, then called Actavis, bought Ireland-headquartered Warner Chilcott...
...Actavis Holdco U.S., Inc.; Actavis Pharma, Inc.; Ascend Laboratories, LLC; Apotex Corp.; Dr....
...However shares in the $84bn US-listed Irish pharma group were held back by the sharp-off in Teva....
...It is still early days for big pharma’s digital push....
...That transaction transformed the company, then known as Actavis, from a manufacturer of generic copycat medicines into a branded drugmaker. “Brent is a bold guy,” says one investor....
...But Mr Holford said this seemed unlikely: “The inversion story feels tired now that the Treasury has twice thwarted large-cap pharma deals.”...
...“We would expect Big Pharma’s current level of R&D spending to become a luxury that investors no longer tolerate,” wrote a group of McKinsey consultants in 2011....
...Last November, drugmaker Actavis clinched a $66bn deal for Allergan, best known for its Botox treatment but whose biggest business was eyecare products (Actavis later rebranded itself as Allergan)....
...Most recently it bought Botox maker Allergan for $70bn and ditched the company’s previous name, Actavis....
...Tim Powell, partner at Powell Gilbert, the law firm that represented Actavis, said the UK ruling provided “welcome clarity in a very complex area of the law”....
...The battle ended with Allergan securing a huge premium from “white knight” bidder Actavis, the generics pharma company, which paid $70.5bn to buy the company in a deal that closed in March....
...“Pfizer scientists will no doubt be aware of Mr Saunders’ historic lack of conviction in pharma-funded research.”...
...The group, which was called Actavis until taking the name of its 2014 purchase, is again on the hunt for deals, armed with the proceeds of the $41bn sale of its generic drugs unit in August....
...The primacy of tax savings over medicines will be seen by many as evidence of big pharma’s warped priorities....
...His rise to the pharma big league has been swift....
...It is just over a year since Brent Saunders became chief executive of Allergan, then known as Actavis, but he has changed the company beyond recognition....
...The distribution of multinationals’ drug products is monopolised in the Philippines by Zuellig Pharma and its affiliate Metro Drug....
...Valeant tried to buy Allergan in a bitter takeover war last year, but lost out to Actavis, which acquired the group for $70bn before adopting its name....
...Others include Actavis, which bought Allergan, the maker of Botox, last year for $66bn and has since adopted the Allergan name....
...A deal, which one person said could be announced within days, would be the latest blockbuster agreement in the pharma sector....
...The ascent of Actavis, based in the US but domiciled in Ireland, speaks to the rise of a different category of drugs company, loosely known as “specialty pharma” by investors....
...For generic manufacturers such as Teva, Mylan and Actavis, the pressure has come from the rise of lower-cost Indian rivals such as Sun Pharma and Cipla....
International Edition